Association of the NOS1AP rs10494366 Genetic Variant With Drug‐Induced QT Prolongation
Clinical and Translational Science · 2026-08 · 19 (8)
DOI: 10.1111/cts.70698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 09.08.2026. Verfasst von Christina A Pippis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Long QT Syndrome, Adaptor Proteins, Signal Transducing, Torsades de Pointes. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Drug‐induced QTc prolongation (diQTP) is a major risk factor for torsades de pointes and sudden cardiac death. This study evaluated whether carriers of the G allele of the NOS1AP rs10494366 T > G variant have greater risk for diQTP when prescribed high‐risk QT‐prolonging medications. A retrospective case‐control analysis was conducted using the Michigan Genomics Initiative (MGI) biobank, linking genotype and electronic health records for 5848 patients of European ancestry prescribed ≥ 1 CredibleMeds high‐risk drug for torsades de pointes between 2001 and 2022. QTc was Bazett‐corrected, and diQTP was defined as change of > 60 ms from the baseline QTc and/or QTc ≥ 500 ms. Associations between rs10494366 and diQTP were tested using unadjusted and propensity‐score‐adjusted logistic regression. The minor‐allele frequency (G) was 0.36, and genotype frequencies were in Hardy–Weinberg equilibrium ( p = 0.07). diQTP occurred in 12.2% of participants. The G allele was not significantly associated with risk of diQTP in either the unadjusted analysis (OR 0.94 [95% CI 0.84–1.05] p = 0.27) or the adjusted analysis (OR 0.94 [95% CI 0.83–1.06] p = 0.30). In this large, real‐world cohort of patients with European ancestry, the NOS1AP rs10494366 variant was not significantly associated with the risk of diQTP. These findings suggest that previously observed associations between this variant and baseline QTc may not extend to all drug‐induced settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Center for Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, Pennsylvania, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Cardiology, Barts Heart Centre, London, UK.
ORCID-Profile: Christina A Pippis, Ana I Lopez-Medina, Choudhary Anwar A Chahal, Jasmine A Luzum
Zitieren
APA
Pippis, C. A., Lopez-Medina, A. I., Chahal, C. A. A., & Luzum, J. A. (2026). Association of the NOS1AP rs10494366 Genetic Variant With Drug‐Induced QT Prolongation. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70698
Vancouver
Pippis CA, Lopez-Medina AI, Chahal CAA, Luzum JA. Association of the NOS1AP rs10494366 Genetic Variant With Drug‐Induced QT Prolongation. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70698
BibTeX
@article{Pippis2026,
author = {Pippis, Christina A and Lopez-Medina, Ana I and Chahal, Choudhary Anwar A and Luzum, Jasmine A},
title = {Association of the NOS1AP rs10494366 Genetic Variant With Drug‐Induced QT Prolongation},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {8},
doi = {10.1111/cts.70698}
}
EUVIMED